The results suggested that the malignancy of hepatocellular carcinoma cells increased when the ligand agonized SLC1A5, and targeting SLC1A5 could alleviate tumor progression in hepatocellular carcinoma patients in the future (44, 45). Here, SLC1A5 is linked to neoplasm.